

Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies

Mariana Barosa¹ | John P. A. Ioannidis² | Vinay Prasad³

¹NOVA Medical School, NOVA University of Lisbon, Lisbon, Portugal

²Departments of Medicine, of Epidemiology and Population Health, of Biomedical Data Science, and of Statistics, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University, Stanford, California, USA

³Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA

Correspondence

Vinay Prasad, University of California, 550 16th St, San Francisco, CA 94158, USA.

Email: vinayak.prasad@ucsf.edu

Funding information

Luso-American Development Foundation; UCSF

Abstract

Annual vaccination is widely recommended for influenza and SARS-CoV-2. In this essay, we analyse and question the prevailing policymaking approach to these respiratory virus vaccines, especially in the United States. Every year, licensed influenza vaccines are reformulated to include specific strains expected to dominate in the season ahead. Updated vaccines are rapidly manufactured and approved without further regulatory requirement of clinical data. Novel vaccines (i.e. new products) typically undergo clinical trials, though generally powered for clinically unimportant outcomes (e.g. lab-confirmed infections, regardless of symptomatology or antibody levels). Eventually, the current and future efficacy of influenza and COVID-19 vaccines against hospitalization or death carries considerable uncertainty. The emergence of highly transmissible SARS-CoV-2 variants and waning vaccine-induced immunity led to plummeting vaccine effectiveness, at least against symptomatic infection, and booster doses have since been widely recommended. No further randomized trials were performed for clinically important outcomes for licensed updated boosters. In both cases, annual vaccine effectiveness estimates are generated by observational research, but observational studies are particularly susceptible to confounding and bias. Well-conducted experimental studies, particularly randomized trials, are necessary to address persistent uncertainties about influenza and COVID-19 vaccines. We propose a new research framework which would render results relevant to the current or future respiratory viral seasons. We demonstrate that experimental studies are feasible by adopting a more pragmatic approach and provide strategies on how to do so. When it comes to implementing policies that seriously impact people's lives, require substantial public resources and/or rely on widespread public acceptance, high evidence standards are desirable.

KEYWORDS

COVID-19 vaccines, health policy, influenza vaccines

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Author(s). *European Journal of Clinical Investigation* published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.

1 | INTRODUCTION

Respiratory viral infections pose a significant burden worldwide. Influenza^{1–3} and respiratory syncytial virus (RSV)⁴ have been major seasonal contributors to massive hospitalizations and deaths every year. The recent 2020 pandemic caused by SARS-CoV-2 claimed millions of lives,⁵ but the burden of COVID-19 has since declined significantly after widespread vaccination and naturally acquired immunity.⁶ Despite major public health efforts, respiratory viral infections continue to place considerable strain on healthcare systems during the winter season, resulting in substantial socioeconomic costs.^{7–9}

Today, yearly vaccination is widely recommended for influenza and SARS-CoV-2 in the United States. Most other countries generally target high-risk populations. Yearly vaccination programmes rely on updated vaccine formulations intended to target future, fall circulating strains. The regulatory basis for approval and justification for population vaccination is typically laboratory or serological experimental studies, followed by post-marketing non-experimental studies.

To lessen the annual burden of respiratory viral infections, both public health experts and the general population must know which preventive measures are most effective. The higher the level of certainty about their effectiveness, the stronger public health recommendations may be (for or against).

In this essay, we analyse and question the prevailing policymaking approach. We generally keep the discussion broad since considering the specifics of every vaccine would not significantly affect our argument; also, specific vulnerable subpopulations (such as those with autoimmune diseases or those who are immunosuppressed) may deserve special considerations^{10–12} and these are outside the scope of this article.

We argue that well-designed and well-conducted experimental studies, particularly randomized trials, are necessary to address unresolved questions for effective vaccine policymaking. We focus on demonstrating how these trials can be feasibly conducted to render results relevant to the current or future respiratory viral season.

2 | ANNUAL RESPIRATORY VIRUS VACCINE DEVELOPMENT

2.1 | Influenza vaccines

The first influenza vaccine approved for non-military individuals was introduced in the United States in 1946.¹³

In 1957, amid worries of the ‘Asian flu’, vaccination became available to the wider public.^{14(p. 39)} In 1963–1964, a federal policy on influenza vaccination for the general population was formulated and has since been updated annually.^{14(p. 39)}

The annual reformulation of influenza vaccines is challenging. Every year, the WHO, the U.S. Food and Drug Administration (FDA), the U.S. Centers for Disease Control and Prevention (CDC) and other public health experts collaborate to identify and select specific influenza strains for inclusion in the new seasonal vaccine, attempting to predict what the prevailing strains will be.¹⁵ After strain selection, manufacturers with licensed influenza vaccines must quickly produce and distribute the updated vaccine.

The production timeline for egg-based and cell-based vaccines is approximately 6 months, of which the last 1–2 months are dedicated to regulatory validation and approval.^{16–18} Recombinant vaccines have shorter manufacturing times, but availability of strain-specific reagents for vaccine potency and release tests may delay their commercial release.¹⁹ Before approval, regulatory agencies verify the vaccine’s identity and potency to ensure standardization. No additional clinical data is typically required, provided that the vaccine composition does not change (e.g. changing the number of antigens in the vaccine or the antigen dose, or adding an adjuvant).^{20–23}

2.2 | COVID-19 vaccines

The first COVID-19 vaccines were developed in 2020 with unprecedented speed. Large randomized controlled trials (RCTs) were rapidly deployed, and few months later robust positive results led to emergency authorizations and subsequent full licensing. From 2021 onwards, the rise of immune evasive variants and waning vaccine-induced immunity²⁴ led to plummeting vaccine effectiveness against symptomatic disease (not necessarily severe disease), and booster doses were widely recommended.²⁵

The first updated COVID-19 vaccines were developed and approved in 2022, supported by emerging real-world effectiveness studies and immunogenicity data. In January 2023, FDA advisors endorsed regular updates of COVID-19 vaccine strain composition.²⁶ In June 2023, an Omicron XBB.1.5-adapted monovalent vaccine was proposed for the 2023–2024 vaccination campaign.²⁷ In September 2023, the vaccine was ready for roll out. Regulatory approval was conceded based on mice immunogenicity data,^{28–33} though later supported by observational research.³⁴

3 | THE CURRENT POLICYMAKING APPROACH AND ITS EVIDENTIARY BASIS

3.1 | Influenza vaccines

Influenza vaccines have been advised on a large scale for decades through massive public health campaigns.¹⁴ Annual vaccination for healthcare workers (HCW) was first recommended in 1984.³⁵ In view of low voluntary uptake, mandatory vaccination emerged. In 2004, the first mandatory seasonal vaccination policy for HCW in the United States was implemented.^{36,37} Since then, influential organizations and medical professional societies, including the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America, have called for mandatory influenza vaccination of HCW³⁸—which in fact became widely adopted in the United States.³⁹ Similar positions were taken in Canada.⁴⁰ In Europe, low coverage rates (<50%) are also commonplace, although mandatory vaccination is infrequent.^{41,42} Some have even called into question the evidence supporting HCW vaccination as a patient safety measure.⁴³

In 2018, Cochrane authors reviewed the evidence supporting influenza vaccines.^{44–46} Specifically, the authors examined 50 trials in healthy individuals under 65 years old, 41 trials in healthy children and 8 RCTs in the elderly (≥ 65 years) comparing influenza vaccines with placebo or no intervention. While vaccines seemingly reduce the risk of influenza-like illness over a single season (from 2.3% to 0.9% in healthy adults, from 17% to 12% for live attenuated vaccines and from 28% to 20% for inactivated vaccines in children, and from 6% to 2.4% in the elderly), data are very limited on the prevention of hospitalization, death, transmission and absence from work. For instance, vaccinated healthy adults may have a small reduction in their risk of hospital admission, but the confidence interval (CI) is wide and crosses one (relative risk [RR] 0.96, 95% CI 0.85–1.08).⁴⁴ For the elderly, there is no data on hospitalizations, and the single randomized trial providing data for mortality and pneumonia was underpowered.⁴⁷ Generally, most estimates in the three reviews are graded low- or moderate-certainty evidence.

More recently, trials have focused on evaluating new vaccines or different strategies against what is considered the standard influenza vaccination approach at the time of the trial. However, the value of these trials remains limited: Either outcomes are clinically unimportant, that is, not patient-relevant (e.g. lab-confirmed infection, regardless of symptomatology and its severity or antibody levels, which are poor predictors of field protection²³), the study design has limitations (typically non-inferiority) and/or follow-up is short.⁴⁸

Midway through the influenza season, efforts are made to assess vaccine effectiveness. Test-negative studies, which use surveillance data, have been increasingly used for this purpose.^{49–51} Vaccination rates are calculated among persons who test positive for influenza (i.e. ‘cases’) and persons with similar illness but who tested negative (i.e. ‘controls’). The ratio of vaccinated to unvaccinated persons is then compared among cases and controls.

Despite the methodological limitations of test-negative studies, which we mention later, these studies have shown that influenza vaccines remain largely suboptimal at preventing infection and severe outcomes. From 2010 to 2023, the estimated adjusted vaccine effectiveness of influenza vaccines against influenza illness among the overall U.S. population ranged between 19% and 60%⁵² (Figure 1). Specifically, during the 2022–2023 season, the CDC estimated overall vaccine effectiveness of 54%. Subsequent assessments yielded a lower value of 46%, being highest for children 6 months to 4 years (54%) and lowest among adults 65 years and older (27%).⁵³ Notably, estimations vary. In one study, protection against influenza A-associated hospitalizations was 23% and 41% among adults aged 18–64 and ≥ 65 years, respectively.⁵⁴ In a different study, the pattern was reversed—47% for people 18–64 years and 28% for those aged 65 and older.⁵⁴ Moreover, given the observational nature of the data, the estimates may be even more uncertain than the typical confidence intervals may suggest.

Despite influenza vaccines being largely safe, policies diverge. Since 2010, CDC advises everybody aged 6 months and older to receive an influenza vaccine (‘universal’ recommendation) on an annual basis.⁵⁵ In turn, the European Centre for Disease Prevention and Control (ECDC) encourages vaccinating high-risk groups only.⁵⁶

3.2 | COVID-19 vaccines

The continuously evolving SARS-CoV-2 variants and the observed seasonal patterns⁵⁷ have earned COVID-19 a yearly influenza-like vaccination approach. In 2022, vaccination campaigns for seasonal boosters emerged.⁵⁸ In 2023, the seasonal vaccine was updated and its uptake strongly encouraged as part of annual fall/winter vaccination campaigns in the United States, United Kingdom, Australia and numerous European countries, including Sweden, Germany, France, Spain, Italy and Portugal.^{59–67}

Randomized data on symptomatic disease allowed initial vaccine approval, yet pivotal trials were not powered to detect differences in hospitalizations or death, and did not include many frail elderly people or people with severe or multiple comorbidities. A few months after the first vaccine rollouts, short-term real-world




FIGURE 1 Effectiveness of seasonal influenza vaccines from 2009 to 2024, when most circulating influenza viruses were well-matched to those used in the vaccine products. Chart including vaccine effectiveness estimates from the United States Flu VE Network across influenza seasons. Data retrieved from Ref. [47]. The dark grey line marks the 50% effectiveness point to illustrate the fact that only 3 out of 14 VE estimates are over 50%. *2020–2021 influenza vaccine effectiveness (VE) was not estimated due to low influenza virus circulation during the 2020–2021 influenza season. **In a Wisconsin study among patients aged 6 months to 64 years, VE was 54% against medically attended outpatient acute respiratory illness (ARI) associated with laboratory-confirmed influenza A. ††VE estimates are preliminary.

observational data suggested that vaccination protected against severe outcomes with large effect sizes (generally over 80% effectiveness, which is substantially higher than that normally observed for influenza vaccines).^{68,69} While such large effect sizes suggest that primary COVID-19 vaccination in 2021 did confer substantive protection against clinically important outcomes, the observational nature of the data should be kept in mind. The exact protection carries more uncertainty than what would have been achieved if these data had been confirmed in an adequately powered randomized trial. Moreover, the duration of the survival benefit is unknown. For example, if the survival benefit was derived mostly from frail people with limited life expectancy, its duration may be short since these people would die soon of other causes.

Additionally, the pivotal Pfizer/BioNTech BNT162b2 (Comirnaty) trial used a different manufacturing process than that used for the vaccines that were widely distributed—termed process 1 and process 2, respectively.⁷⁰ Process 2 was developed in order to upscale vaccine production. However, some have voiced concerns about the product quality and efficacy/safety of Process 2 vaccines.⁷⁰ Comparative immunogenicity and safety analyses were planned, according to a protocol amendment to the foregoing trial.⁷¹ Nevertheless, to the best of our knowledge, results have never been published. These manufacturing process differences may cast some doubt into the Pfizer's

trial results and which conclusions can be drawn from them.

Since the licensure of the first COVID-19 vaccines, observational data have been used to estimate vaccine effectiveness. In September 2023, the CDC concluded that vaccination of adults and adolescents with the 2023–2024 updated vaccine was beneficial based on pooled estimates from retrospective cohort or test-negative studies.⁷² These estimates find relative risks of 0.5 for medically attended COVID-19 (95% CI 0.4–0.5) and COVID-19 hospitalizations (95% CI 0.4–0.7), and 60% lower risk of death (RR 0.4, 95% CI 0.3–0.6).

However, several aspects of the CDC's evidence review and conclusion raise concerns. All estimates were considered either 'low certainty' or 'very low certainty'. COVID-19 was not necessarily confirmed as the cause of hospitalizations. Absolute risk was calculated using the observed risk among a single observational cohort in the available body of evidence. The absolute risk reduction is relatively low—186 fewer COVID-19 visits, 53 fewer hospitalizations and six fewer deaths per 100,000. Finally, the studies included in the review evaluated vaccine effectiveness of the previous COVID-19 vaccine (bivalent Original and Omicron BA.4/BA.5).

A randomized trial of a third dose of the BNT162b2 mRNA vaccine versus placebo in 10,136 people who had previously received two doses of the vaccine showed spectacular short-term efficacy in lab-confirmed

infections (6 vs. 123 in the two arms, with median follow-up of 2.5 months), but no data on hospitalizations or deaths (only 1 death occurred, unrelated to the intervention).⁷³ Despite substantial heterogeneity in COVID-19 booster studies,⁷⁴ further observational analyses support the idea that repeated boosting reduces the risk of complications from COVID-19 in the short term, although vaccine-induced immunity rapidly wanes.^{54,75,76} Among previously infected people, a study in the entire population of Austria showed small vaccine effectiveness for COVID-19 infections (17%) in the first 2 months that was reversed with longer follow-up to 8 months. There was no benefit for COVID-19 deaths, despite the results being biased towards overestimation of benefits due to healthy vaccinee bias (i.e. a propensity for healthier individuals to be more likely to get vaccinated than those who are less healthy).⁷⁷

No published RCT has investigated to-date the benefits of COVID-19 boosters versus no boosters on clinically relevant outcomes (severe disease, hospitalization and death), and whether any potential benefits apply the same way to different groups. It is unclear whether healthy adults, young people and even the elderly benefit from receiving boosters now that almost everyone worldwide has already been previously infected.

3.3 | Both influenza and COVID-19 vaccines share a questionable policy approach

The fact that both influenza and COVID-19 annual vaccination policies rely on observational evidence is problematic. Observational studies are particularly susceptible to confounding and other biases (for an overview, see Ref. [78]), and there are complex difficulties faced by non-randomized studies in estimating the effectiveness of COVID-19 vaccines. The healthy vaccinee bias was particularly evident in a large 2021 cohort study reporting 94.6% lower mortality with COVID-19 boosters,⁷⁹ and in which non-COVID-19 mortality was also similarly 94.8% lower in those who received the booster.⁸⁰

The test-negative design has been the observational design of choice for studying effectiveness of respiratory virus vaccines. Compared with other observational designs, test-negative studies reduce confounding and selection bias from health-seeking behaviour differences (like the healthy vaccinee effect), misclassification of case status and recall bias.⁸¹

However, the test-negative study design is still vulnerable to significant confounding, namely due to differential health-seeking behaviour, which typically

inflates vaccine effectiveness.^{48,82–86} For example, the design only includes persons who access healthcare services (in the US, unemployed individuals or people with limited insurance are less likely to seek healthcare, or vaccinated people may be more health-seeking and thus healthier) and ignores the prior exposure history of patients.⁸¹ Or the cluster of symptoms that determines who gets tested for respiratory viruses may be narrowly restricted to certain respiratory symptoms or vary between places. Thus, true background rates of infection are unknown, and cases and controls are likely different populations at baseline.

In addition to these limitations, several important scientific questions remain unaddressed. These include the magnitude and duration of protection from different vaccine products or vaccination strategies, how effective vaccines are against new variants, the comparative effectiveness between different vaccine formulations, doses and/or vaccination schedules, and even the long-term immune consequences of repeated immunizations. In our view, because of persistent uncertainties, COVID-19 vaccination policies differ between countries, especially between the United States and several European countries. While the CDC has opted for universal vaccination recommendations, many European countries have targeted high-risk populations. In Table 1, we contrast fall/winter COVID-19 vaccination programmes for the 2023–2024 season across 10 countries.

Both influenza and COVID-19 are vaccine-preventable diseases to some extent, but the two conditions and their respective vaccines differ in several respects. Compared to influenza, COVID-19 exhibits a steeper age-related risk gradient for severity of disease,^{89,90} as influenza carries greater global death burden for children.⁹¹ Moreover, COVID-19 vaccines have greater effectiveness in unvaccinated people,^{44–46,92} significantly more reactogenicity than influenza vaccines (Figure 2), and at least one serious, albeit still relatively understudied, safety concern, that is, myocarditis in the young,⁹⁹ though others have been raised (e.g. heavy menstrual bleeding with mRNA vaccines¹⁰⁰). Moreover, there is little high-quality evidence that boosters further reduce severe disease and hospitalization among persons who previously had COVID-19, and most people have likely been infected at least once. These differences emphasize the importance of studying a policy approach for COVID-19 vaccination that considers individual aspects of the disease, rather than assuming that influenza vaccination policies can be equally applied to COVID-19.

Several experts have been critical of yearly COVID-19 universal vaccination policies. In 2021, two FDA regulators resigned in protest against universal boosting.¹⁰¹

TABLE 1 2023 fall/winter COVID-19 booster programmes in 10 different countries (northern hemisphere).

Country	Date	Recommendation
United States	12 September 2023	Updated COVID-19 vaccine* for everyone ≥6 months old (CDC recommendation) ⁵⁸
United Kingdom	26 May 2023 updated on 5 October 2023	<p>Updated COVID-19 vaccine* for those at increased risk of serious disease from COVID-19:</p> <ul style="list-style-type: none"> • Residents in a care home for older adults • All adults ≥65 years • Persons aged 6 months to 64 years in a clinical risk group (defined) • Frontline health and social care workers • Persons aged 12–64 years who are household contacts of people with immunosuppression • Persons aged 16–64 years who are carers and staff working in care homes for older adults (JCVI recommendation)⁵⁹
Canada	11 July 2023 updated on 12 September 2023	<p>Updated COVID-19 vaccine* recommended for those ≥6 months old, if it has been at least 6 months since last COVID-19 vaccine or infection. Immunization is strongly recommended—i.e. should be offered—for those at increased risk of COVID-19 infection or severe disease:</p> <ul style="list-style-type: none"> • Adults ≥65 years • Residents of long-term care homes and other congregate living settings • Individuals with underlying medical conditions that place them at higher risk of severe COVID-19 • Pregnant • Individuals in or from First Nations, Métis and Inuit communities • Members of racialized and other equity-deserving communities • People who provide essential community services (NACI recommendation)⁸⁷
Sweden	1 October 2023 updated on 16 November 2023	<p>Vaccination against COVID-19 (vaccine composition unspecified) if:</p> <ul style="list-style-type: none"> • ≥65 years • >18 years old and certain medical conditions (defined) • Never been vaccinated against Covid-19 and are ≥50 years • Pregnancy (>12 weeks) (Swedish Public Health Agency)⁶¹
Denmark	1 October 2023 updated on 25 October 2023	<p>Updated COVID-19 vaccine* for:</p> <p>Persons ≥65 years</p> <ul style="list-style-type: none"> • Persons below 65 years with some chronic conditions (defined) • Persons with severe obesity (BMI > 35) • Persons with other serious disease or conditions, e.g. persons with severe mental illness, Down's syndrome or severe abuse • Pregnant women in their 2nd or 3rd trimester if they have not previously received COVID-19 vaccination or carry other risk factors • Persons in the household of persons with congenital or acquired immunodeficiency and children at an increased risk of severe influenza or COVID-19 • Stem cell transplantation recipients should be offered two doses of Cominaty Omicron XBB.1.5 given at a minimum interval of 3 weeks, followed by seasonal vaccination (a third dose) no less than 8 weeks after the second dose was given (Statens Serum Institut, Danish Ministry of Health)⁸⁸

TABLE 1 (Continued)

Country	Date	Recommendation
Italy	14 August 2023 updated on 27 September 2023	<p>Updated COVID-19 vaccine* in those with last dose >6 months, if:</p> <ul style="list-style-type: none"> • Adults ≥60 years • Residents of long-term care homes • Pregnant women (any semester) or in post-partum period, including those breastfeeding • Front-line health and social care workers in hospitals, local areas and long-term care facilities; medical students or other students/in terms rotating in healthcare facilities • Persons aged 6 months to 59 years, with high frailty motivated by concomitant/pre-existing conditions (defined) • Family members or carers of persons with severe frailty (Italian Ministry of Health)⁶⁵
France	23 February 2023 updated on 10 October 2023	<p>Updated COVID-19 vaccine* in those with last dose >6 months, if:</p> <ul style="list-style-type: none"> • Person ≥65 years • Immunocompromised people • Pregnant woman • Resident in a residential care facility for dependent older adults and a long-term care unit • Person at very high risk of severe illness based on each individual medical situation and in a decision shared with health care teams • Person living in close contact or in regular contact with immunocompromised or vulnerable people, including health and medical professionals • ≥6 months of age with comorbidities <p>Free vaccination is offered to all those who wish (French Ministry of Labor, Health and Solidarity)⁶³</p>
Germany	18 September 2023	<p>Updated COVID-19 vaccine,* generally at least 12 months after the previous vaccination or infection, for:</p> <ul style="list-style-type: none"> • Adults ≥60 years • Residents of long-term care facilities • Anyone over the age of 6 months with an underlying condition (defined) • People of all ages with an increased infection risk on account of their occupation in medical or long-term care • Family members and close contacts of people for whom the COVID-19 vaccination is unlikely to produce a protective immune response (STIKO, German Federal Ministry of Health)⁶²
Spain	12 September 2023	<p>Updated COVID-19 vaccine* for:</p> <ul style="list-style-type: none"> • Persons ≥60 years • Persons ≥5 years old living in disability centres and nursing homes, as well as other long-term institutionalized people • People <60 years with risk conditions (defined) • Pregnant women (any semester) or post-partum period (Spanish Ministry of Health)⁶⁴
Portugal	13 September 2023 Updated on 12 January 2024	<p>Updated COVID-19 vaccine* for:</p> <ul style="list-style-type: none"> • Persons ≥60 years • Residents and professionals of nursing homes and long-term care facilities • Those >12 years old with the comorbidities (defined) • Pregnant women ≥18 with comorbidities (defined) • Health professionals and care providers • Vaccination is offered to all those who wish (Direção-Geral de Saúde, Portuguese Ministry of Health)⁶⁶

Abbreviations: ATAGI, Australian Technical Advisory Group on Immunisation; CDC, Centers for Disease Control and Prevention; JCVI, Joint Committee on Vaccination and Immunisation; NACI, National Advisory Committee on Immunization; STIKO, Standing Committee on Vaccination.

*2023–2024 vaccine formulation (Omicron XBB.1.5).

COVID-19 vaccines			Influenza vaccines ^f		
	Severe reactions	Relative risk ^e		Severe reactions ^g	
Primary series	Pfizer 16+	10,7% ^a	4,76	Inactivated (egg-based or cell-cultured) (including high-dose or adjuvanted)	~ 0–3.7%
	Moderna 18+	21,3% ^a	4,77	Recombinant	≤ 1%
	Booster doses ^{b,c,d}	0–10%			

FIGURE 2 Comparative reactogenicity between COVID-19 and influenza vaccines in adults (grade ≥ 3 , i.e. participant cannot carry out usual activities). Severe reactions with COVID-19 vaccines appear to be more common than with influenza vaccines, although data for recent COVID-19 boosters is limited. ^aCalculated from reported data in Ref. [93]. Reactogenicity data are from the original monovalent randomized controlled trials. The CDC evidence review considered that for subsequent or updated vaccines, data were very limited. ^bSee Ref. [94]. ^cSee Ref. [95]. ^dSee Ref. [96]. ^eRelative risk to control arm. ^fNo systematic review of influenza vaccines' reactogenicity is available, data are scattered and definitions vary. ^gRough estimates based on a non-systematic review of available data, which include different types of influenza vaccines and different adult age ranges. See Refs. [97] and [98].

Paul Offit, one member of the FDA Vaccine Advisory Committee, has been publicly expressing his concerns.¹⁰² In September 2023, Offit reiterated that vaccination policies should be focusing on high-risk groups, who are most likely to suffer serious disease.¹⁰³ Such a targeted approach is advocated by the WHO and several European countries (Table 1). In January 2024, two FDA leaders expressed regret over the low uptake of 2023–2024 respiratory virus vaccines in the United States, especially among the elderly (around 35% uptake), which is not seen in the United Kingdom, for instance.¹⁰⁴ These concerns deserve serious reflection about whether the push for universal vaccination with limited supporting evidence may be eroding trust in public health authorities.

4 | CLINICAL TRIALS ARE NECESSARY AND FEASIBLE

To reduce or resolve persistent uncertainties about the benefits of influenza and COVID-19 vaccines, additional experimental studies are necessary, especially RCTs. Randomization has the ability to adequately control for diverse known and unknown confounding factors.^{105,106}

According to the principle of equipoise, trials can be conducted in a situation of uncertainty and/or disagreement among experts about the evidence regarding an experimental intervention.¹⁰⁷ To disturb equipoise, well-designed experimental studies are needed, even during public health emergencies.^{108,109}

The COVID-19 pandemic showed that international collaboration and team efforts to implement large trials, like the WHO's SOLIDARITY or UK RECOVERY, could quickly generate practice-changing evidence within

6 months.¹⁰⁸ However, one may argue that 6 months far exceeds the time manufacturers have to run a trial testing the updated seasonal vaccine before regulatory approval and vaccine roll out, and indeed, this time horizon may be shortened with larger recruitment in RCTs.

For our purposes, let us draw a distinction between novel and updated influenza vaccines. Novel vaccines are new products, usually with a new composition (e.g. a different number of antigens, new antigen dose, new adjuvant) or novel manufacturing process, which undergo clinical trials before approval. Yet, these trials are problematic because they are often powered to show non-inferiority for surrogate outcomes such as antibody levels, when antibody responses are poor predictors of field protection.²³ To illustrate, the Fluzone[®] High-Dose vaccine was approved in 2009 for people over 65 years old because it proved to elicit higher antibody titres than the standard dose formulation.¹¹⁰ In 2019, a novel quadrivalent formulation (Fluzone[®] High-Dose Quadrivalent) was licensed based on the demonstration of a non-inferior immune response at 28 days post-vaccination and comparable safety with respect to trivalent high-dose formulations.¹¹¹


Updated vaccines, that is, vaccines which underwent strain update 'only' through the same manufacturing process, can be approved without clinical efficacy data.^{21,23} For instance, the recombinant influenza vaccine Flubok[®] was first licensed in the United States in 2013 after meeting FDA's requirements for immunogenicity, effectiveness (against documented mild influenza illness) and safety.¹¹² The following year, the manufacturer reformulated the vaccine to include the latest circulating strains and the updated vaccine was approved for distribution based on non-clinical data, following

the standard process of annual updating of seasonal influenza vaccines.^{21,113}

In both cases, what is most needed is robust effectiveness data on important clinical endpoints, such as severe illness, hospitalizations and death. This can be achieved in two different ways, depending on whether a novel or

updated vaccine is being considered. In Figure 3, we propose a research framework for seasonal influenza vaccines that could secure high evidentiary standards. For novel vaccine candidates, phase III trials may start early in the season and must be powered for clinically relevant outcomes. With robust enrolment, these trials could yield

Status quo for yearly influenza vaccines approval



New research framework for yearly influenza vaccines approval and policy revision




FIGURE 3 Research framework for seasonal influenza vaccines to secure high evidentiary standards for policymaking. Ab, antibody; RCT, randomized clinical trial; *Includes vaccine potency and release tests, as well as quality control; ++, preferably.

results in time to inform policy decisions within a single influenza season. For updated vaccines, well-conducted trials can compare multiple vaccine strategies during one season and encourage policy revisions for upcoming seasons. Different strategies may be compared for the same updated vaccine (e.g. different schedules) or, in some cases, between different updated vaccines (e.g. egg-based versus recombinant). However, it must not be assumed that all licensed updated vaccines have similar efficacy to one another.

In the quest of generating evidence as early as possible to inform about vaccine efficacy during an ongoing season, one should carefully think in advance about whether (and if so, when) interim analyses may be performed. Interim analyses need to anticipate adjustments in efficacy results, since early stopping generates inflated estimates of efficacy.¹¹⁴ Genuine waning of efficacy over time should also be considered. To study the magnitude of the potential waning, one may need to avoid unblinding the trial after such early interim analyses. Regardless, the overall design, including the specific action plans after interim analyses, should be thoroughly vetted through ethical review and fully informed consent of participants.

This argument extends also to new or updated COVID-19 vaccines. Next, we suggest suitable clinical trial designs that can address uncertainties around respiratory virus vaccines and be feasibly conducted.

4.1 | Suitable and feasible trial designs

Pragmatic trials designed to inform about decisions in real-world practice¹¹⁵ are particularly appropriate to address uncertainties around respiratory virus vaccines. Certain elements, such as adaptive and platform trial designs, cluster randomization and use of existing registries, can accelerate enrolment, address heterogeneous populations in real-life scenarios, accommodate complex interventions and potentially reduce overall research costs.¹¹⁶

While scarce, there have been pragmatic attempts at generating new, relevant and reliable evidence about influenza vaccines. A Danish research team conducted a pilot trial (DANFLU-1 trial) to investigate the feasibility of conducting a large-scale pragmatic trial in Denmark comparing two different dosing strategies in patients over 65 years old.^{117,118} The results were highly encouraging. By integrating an individually randomized trial into routine seasonal influenza vaccination practice and using nationwide administrative health registries, the investigators achieved astonishing recruitment rates in the first 15 days—median of 674 patients per day,¹¹⁹ approximately

11.4 patients per 100,000 inhabitants per day. Assuming the same population rate of enrolment in the United States one could imagine enrolment of 38,900 patients per day during the month of September. The ongoing DANFLU-2 trial aims to build upon DANFLU-1 with a multi-season study of >200,000 older adults powered for severe clinical outcomes.¹²⁰

Countries with pre-existing nationwide population registries (e.g. several Scandinavian countries, Taiwan, and South Korea¹²¹) have an advantage in rapidly conducting large pragmatic trials, readily embedding them in their registries. These trials could then contribute to global decision-making. However, large-scale pragmatic trials can also be performed in countries lacking nationwide registries, such as the United States, by using other existing large-scale structures, for example, the military or healthcare organizations. For example, the Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD (PAIVED) trial is a 4-year randomized clinical trial of three FDA-licensed vaccine types (egg-based, cell-based and recombinant), designed to identify the most effective influenza vaccine platform for adults in a military setting.¹²²

Cluster randomization has also been used. One trial evaluated the impact of care home staff vaccination on residents' all-cause mortality (rate difference: -5.0 per 100 residents, 95% CI: -7.0 to -2.0), influenza-like illness (-9.0 per 100 residents, -14.0 to -3.0) and health service use over two seasons (general practitioner consultations for influenza-like illness (-7.0 , -12.0 to -2.0) and admissions to hospital with influenza-like illness (-2.0 , -3.0 to 0)).¹²³ Another trial randomized 823 US facilities over a single season (2013–2014) to compare the effect of high-dose vaccines with standard-dose ones on hospital admissions among nursing home residents.¹²⁴ More recently, a Kaiser Permanente-based, industry-funded, study compared high-dose recombinant with standard-dose vaccines in adults ≤ 65 years old, including 1,630,328 participants over three seasons (2018–2021).¹²⁵

For assessing comparative vaccine effectiveness in high-risk populations where hospitalization and death events are frequent, pragmatic trials can be run also with much smaller sample sizes, as in the case of a well-performed pragmatic trial comparing two influenza vaccines in 5260 patients with high-risk cardiovascular disease.¹²⁶

These cases demonstrate that RCTs are feasible and not prohibitively expensive if one incorporates pragmatic elements. Most such trials may compare different active interventions or strategies, but comparisons against no vaccination are also possible, in settings and populations deemed ethically appropriate with equipoise. While

TABLE 2 Examples of unresolved research questions regarding respiratory virus vaccines and how comparative research could address them.

Research question	Description of research	Example of trial
<p>What is the best type of vaccine product/ route of administration for influenza vaccines?</p> <ul style="list-style-type: none"> • Inactivated • Live attenuated • Live aerosol • Recombinant • Adjuvanted 	Comparison between different vaccine products and/or routes of administrations, possibly in different populations	Multiarm, registry-based, RCT comparing inactivated high-dose, adjuvanted and recombinant in the elderly (65+) powered for clinically relevant outcomes Cluster RCT comparing adjuvanted vs. recombinant vaccines, against severe illness in the elderly (65+). Cluster randomization of vaccination facilities
<p>Which outcomes do we want to prevent?</p> <ul style="list-style-type: none"> • Viral specific outcomes • General health (ILI) and quality of life outcomes • Absenteeism 	Powering trials for clinically relevant and/or public health related outcomes	Multisite (perhaps also multinational), placebo-controlled, cluster RCT testing the effectiveness of a given COVID-19 updated vaccine against severe illness, hospitalizations, and death in high-risk populations (65+ and those with pre-specified comorbidities) RCT in healthy adults or healthcare staff assessing working days lost
<p>What is the magnitude of protection (against)?</p> <ul style="list-style-type: none"> • Symptomatic infection • Severe disease/hospitalization • Death • Transmission (laboratory confirmation) • Absence from work • Other 		RCT for effectiveness of COVID-19 boosters in older patients (50+), powered for severe disease and hospitalizations Cluster RCT for effectiveness of influenza vaccines to prevent in-hospital/nosocomial transmission; randomize different internal/general medicine wards to either staff vaccination or placebo during 1 or more seasons. Primary outcome: number of symptomatic influenza infections in patients; secondary outcome: days lost from work
<p>What is the duration of protection?</p> <ul style="list-style-type: none"> • Against asymptomatic/mild infection • Against severe disease 	Testing via prolongation of control arms	Stepped wedge, 5-year, cluster RCT where HCW in different hospitals are randomized to annual influenza vaccination policy or no vaccination in a stepped way: every year, new hospitals are randomized to either annual HCW vaccination or no intervention. Outcomes: symptomatic infection in HCW, incidence of ED admissions for respiratory disease, incidence of in-hospital influenza infections
<p>Which populations deserve special attention?</p> <ul style="list-style-type: none"> • Children • Healthy adults • Healthcare workers • Older patients (50+) • Elderly (65+) • Immunocompromised • Other 	Selection of special populations for study in different trials	(Any trial in this column; selecting one population that deserves special attention)
<p>What is the best vaccine composition?</p> <ul style="list-style-type: none"> • Trivalent (includes and targets 3 influenza strains) • Quadrivalent (includes and targets 4 influenza strains) • Universal (under development, targets all influenza strains) • Standard dose • Other doses • Weight-based dose 	Comparison between different vaccine products, doses or regimens	Multiarm, adaptive, RCT comparing dose 1, dose 2, dose 3 and weight-based dosing of a recombinant influenza vaccine in a phase II/III design. In the phase III stage, the population is categorized into low- and high-risk and two interim analyses (IA) are planned. Each subpopulation is randomized to one arm. First IA = futility check (one subpopulations/arm may fail to continue). Second IA = another futility check + early efficacy claim

(Continues)

TABLE 2 (Continued)

Research question	Description of research	Example of trial
What is the best way of selecting strains? (hypothetical examples) <ul style="list-style-type: none"> • Algorithm 1 • Algorithm 2 • Algorithm 3, etc. 	Comparison between different computer algorithms for predicting the most dominant strains in the upcoming season based on epidemiological data	RCT where vaccine manufacturers are randomized to either producing vaccines that include strains predicted by algorithm 1 (usual method) or by algorithm 2. Both vaccines are distributed. Outcomes: antigenic match to fall/winter circulating strain and clinical outcomes
What is the best vaccination schedule? <ul style="list-style-type: none"> • 6 months • 12 months • 24 months • Other 	Comparison between different vaccination schedules	Cluster RCT comparing influenza vaccine effectiveness against severe outcomes in those scheduled for annual vaccination (12 months) and those for biennial vaccination (24 months)
Which setting confers higher risk of exposure? <ul style="list-style-type: none"> • Challenge • High risk environment (nursing home/ health care/ dorm) • Community 	Comparison between different exposure settings	RCT, 2×2 factorial design, assessing symptomatic infection in healthy young adults living in dorms randomized to vaccination or no vaccination and then to either exposure (contact with influenza patients) or no exposure

Abbreviations: HCW, healthcare workers; ILI, influenza-like illness; RCT, randomized controlled trial.

including a placebo arm in future influenza vaccine trials is controversial, we suppose a placebo arm could be considered where evidence of vaccine effectiveness is most uncertain, in line with the ethical principle of equipoise. The same applies to COVID-19 vaccines. Given the absence of high-quality evidence that repeated boosting with updated COVID-19 vaccines protects against severe outcomes, even in high-risk populations, placebo-controlled trials may be deemed ethical. One may also argue that comparison of vaccines should be against no vaccination rather than a placebo, since ‘vaccination or no vaccination’ is precisely the pragmatic clinical decision that millions of people make each year and placebo trials have lower pragmatism.¹²⁷ Nevertheless, comparing vaccination to no vaccination in a trial setting is not devoid of challenges, in particular the risk of performance bias.

In running such trials, one should be aware of some residual caveats,¹²⁸ for example, trials using routinely collected data may provide lower estimates of effectiveness compared with traditional trials.^{128,129} However, this can be anticipated in the sample size calculations. Moreover, observed estimates of effectiveness eventually may be more relevant about what can be achieved in real-world circumstances.

Platform trials bring promise to making respiratory virus vaccine research more efficient. One can envision multi-organizational and cross-company collaborative efforts to launch a platform trial where new vaccines are incorporated in the same trial structure as they become available, and where, among other adaptations, interventions are added or discontinued based on interim analyses.¹³⁰

Table 2 lists a number of unresolved questions surrounding respiratory virus vaccinations along with proposed trials that could address these questions. Many of these trials test different strategies for mass vaccination campaigns—information that indirectly assess the effectiveness of seasonal vaccines. Ultimately, all of these strategies can be employed to yield a more information rich environment than the current system.

5 | CONCLUSION

In this essay, we demonstrated the necessity of generating strong evidence to support yearly respiratory virus vaccination, and have provided some strategies on how to do so. Current annual policies are supported by limited evidence. Manufacturers have little incentive to run RCTs powered for clinically important outcomes which might show their vaccines are ineffective—unless regulatory or public health agencies, who have the authority, require them to.

Probably policymakers will also march forward with RSV annual vaccination programmes. In 2023, RSV vaccines showed their first signs of clinical benefit in the elderly. Emerging data suggest that one dose of the adjuvanted vaccine could protect for more than one season,¹³¹ which might have major implications for policymaking. Uncertainty about the duration of protection from RSV vaccines typifies a situation requiring proper investigation in an experimental setting.

We do not wish to reduce the complexity of policymaking and clinical decision-making to a matter of

running more RCTs. Different designs, randomized and other, can offer complementary evidence. However, healthcare policies and medical practices should be as best informed as possible. Scientists and policymakers should keep the bar high when implementing policies that seriously impact people's lives, require substantial public resources and/or rely on widespread public acceptance.

AUTHOR CONTRIBUTIONS

MB and VP conceptualized the article. MB wrote the first draft. VP and JPAI did substantial editing. All authors contributed to the writing, review, editing and analysis of the manuscript.

ACKNOWLEDGEMENTS

We are grateful for the valuable contributions the reviewers, whose critical comments helped us considerably improve this manuscript.

FUNDING INFORMATION

MB received a research grant from Luso-American Development Foundation (FLAD). The work of JPAI is supported by an unrestricted gift from Sue and Bob O'Donnell to Stanford University. VP receives research funding from Arnold Ventures through a grant made to UCSF, and royalties for books and writing from Johns Hopkins Press, MedPage and the Free Press; he declares consultancy roles with UnitedHealthcare and OptumRX; and he hosts the podcasts, Plenary Session, VPZD, Sensible Medicine; writes the newsletters, Sensible Medicine, the Drug Development Letter and VP's Observations and Thoughts; and runs the YouTube channel Vinay Prasad MD MPH, which collectively earn revenue on the platforms: Patreon, YouTube and Substack.

CONFLICT OF INTEREST STATEMENT

The authors have no conflict of interest to declare.

ORCID

Mariana Barosa  <https://orcid.org/0000-0001-7729-448X>

[org/0000-0001-7729-448X](https://orcid.org/0000-0001-7729-448X)

John P. A. Ioannidis  <https://orcid.org/0000-0003-3118-6859>

[org/0000-0003-3118-6859](https://orcid.org/0000-0003-3118-6859)

Vinay Prasad  <https://orcid.org/0000-0002-6110-8221>

REFERENCES

- Cassini A, Colzani E, Pini A, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the burden of communicable diseases in Europe study, European Union and European economic area countries, 2009 to 2013. *Euro Surveill.* 2018;23(16):17-00454. doi:10.2807/1560-7917.ES.2018.23.16.17-00454
- Centers for Disease Control and Prevention. Frequently asked questions about estimated flu burden. 2021. Accessed December 15, 2023. <https://www.cdc.gov/flu/about/burden/faq.htm>
- World Health Organization. Global Influenza programme. Accessed December 15, 2023. <https://www.who.int/teams/global-influenza-programme/surveillance-and-monitoring/burden-of-disease>
- Centers for Disease Control and Prevention. RSV Surveillance & Research Published. 2023 Accessed December 15, 2023. <https://www.cdc.gov/rsv/research/index.html>
- World Health Organization. 14.9 million excess deaths associated with the COVID-19 pandemic in 2020 and 2021. Accessed December 15, 2023. <https://www.who.int/news/item/05-05-2022-14.9-million-excess-deaths-were-associated-with-the-covid-19-pandemic-in-2020-and-2021#:~:text=New%20estimates%20from%20the%20World,13.3%20million%20to%2016.6%20million>
- Ioannidis JPA. The end of the COVID-19 pandemic. *Eur J Clin Invest.* 2022;52(6):e13782. doi:10.1111/eci.13782
- Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of respiratory viral infections. *Annu Rev Virol.* 2020;7(1):83-101. doi:10.1146/annurev-virology-012420-022445
- Zimmerman RK, Balasubramani GK, D'Agostino HEA, et al. Population-based hospitalization burden estimates for respiratory viruses, 2015–2019. *Influenza Other Respir Viruses.* 2022;16(6):1133-1140. doi:10.1111/irv.13040
- Birnbaum H, Morley M, Greenberg P, Colice G. Economic burden of respiratory infections in an employed population. *Chest.* 2002;122:603-611. doi:10.1378/chest.122.2.603
- Murdaca G, Noberasco G, Olobardi D, et al. Current take on systemic sclerosis Patients' vaccination recommendations. *Vaccine.* 2021;9(12):1426. doi:10.3390/vaccines9121426
- Murdaca G, Orsi A, Spanò F, et al. Vaccine-preventable infections in systemic lupus erythematosus. *Hum Vaccin Immunother.* 2016;12(3):632-643. doi:10.1080/21645515.2015.107685
- van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. *Ann Rheum Dis.* 2011;70(3):414-422. doi:10.1136/ard.2010.137216
- The history of influenza. 2023. Accessed December 16, 2023. <https://www.flu.com/Articles/2022/The-History-of-Influenza>
- Doshi PN. Influenza: A study of contemporary medical politics. Thesis. Massachusetts Institute of Technology 2011. Accessed December 7, 2023. <https://dspace.mit.edu/handle/1721.1/69811>
- Food and Drug Administration. It's a good time to get your flu vaccine. 2023. Accessed December 16, 2023. <https://www.fda.gov/consumers/consumer-updates/its-good-time-get-your-flu-vaccine>
- Centers for Disease Control and Prevention. Selecting viruses for the seasonal influenza vaccine. 2022. Accessed December 16, 2023. <https://www.cdc.gov/flu/prevent/vaccine-selection.htm>
- Food and Drug Administration. FDA's critical role in ensuring supply of influenza vaccine. 2022. Accessed December 16, 2023. <https://www.fda.gov/consumers/consumer-updates/fdas-critical-role-ensuring-supply-influenza-vaccine>
- World Health Organization. Pandemic influenza vaccine manufacturing process and timeline. 2009. Accessed January 20,

2024. <https://www.who.int/news/item/06-08-2009-pandemic-influenza-vaccine-manufacturing-process-and-timeline#>
19. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: formulation and production strategies. *Eur J Pharm Biopharm.* 2015;94:251-263.
 20. Khurana S. Development and regulation of novel influenza virus vaccines: a United States young scientist perspective. *Vaccine.* 2018;6(2):24. doi:10.3390/vaccines6020024
 21. Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. *Influenza Other Respir Viruses.* 2016;10(5):354-360. doi:10.1111/irv.12383
 22. 183rd meeting of the vaccines and related biological products advisory committee. 2023. Accessed January 10, 2023. <https://www.youtube.com/watch?v=3MRqhXOB3IQ>
 23. Committee for Medicinal Products for Human Use. Guideline on influenza vaccines - non-clinical and clinical module. Published online July 21, 2016. Accessed January 8, 2024. https://www.ema.europa.eu/en/documents/scientific-guide-line/influenza-vaccines-non-clinical-and-clinical-module_en.pdf
 24. Thomas SJ, Moreira ED, Nicholas K, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. *N Engl J Med.* 2021;385(19):1761-1773. doi:10.1056/NEJMoa2110345
 25. Prasad V. COVID-19 vaccines: history of the pandemic's great scientific success & flawed policy implementation. Published Online December 6, 2022. doi:10.5281/zenodo.7405924
 26. Rubin R. Questions remain about what SARS-CoV-2 variants should go into the annual COVID-19 vaccines proposed by the FDA. *JAMA.* 2023;329(9):697-700. doi:10.1001/jama.2022.22285
 27. Vaccines and Related Biological Products Advisory Committee Meeting. Selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023–2024 vaccination campaign. 2023. Food and Drug Administration. Accessed January 12, 2023. <https://www.fda.gov/media/169378/download>
 28. Modjarrad K. Monovalent XBB.1.5 BNT162b2 COVID-19 vaccine. Presented at: ACIP Meeting; September 12, 2023. Accessed January 17, 2023. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-09-12/10-COVID-Modjarrad-508.pdf>
 29. Food and Drug Administration. FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants. Published September 11, 2023. Accessed January 6, 2024. <https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating>
 30. Kaslow DC. Emergency Use Authorization (EUA) for an unapproved product review memorandum - Pfizer-BioNTech COVID-19 vaccine (2023–2024 Formula). Published online June 23, 2023. Accessed January 6, 2023. <https://www.fda.gov/media/172019/download?attachment>
 31. European Medicines Agency. COVID-19 medicines. Published 2023. Accessed January 6, 2024. <https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines>
 32. Medicines and Healthcare products Regulatory Agency. MHRA approves Moderna's adapted COVID-19 vaccine (Spikevax) that targets Omicron XBB.1.5. GOV.UK. Published September 15, 2023. Accessed January 6, 2024. <https://www.gov.uk/government/news/mhra-approves-modernas-adapted-covid-19-vaccine-spikevax-that-targets-omicron-xbb15>
 33. Medicines and Healthcare products Regulatory Agency. MHRA approves Pfizer/BioNTech's adapted COVID-19 vaccine (Comirnaty) that targets Omicron XBB.1.5. Published September 5, 2023. Accessed January 6, 2024. <https://www.gov.uk/government/news/mhra-approves-pfizerbiontechs-adapted-covid-19-vaccine-comirnaty-that-targets-omicron-xbb15>
 34. Tartof SY, Slezak JM, Frankland TB, et al. BNT162b2 XBB1.5-adapted vaccine and COVID-19 hospital admissions and ambulatory visits in US adults. Published online December 28, 2023:2023.12.24.23300512. doi:10.1101/2023.12.24.23300512
 35. Immunisation Practices Advisory Committee. Recommendation of the immunization practices advisory committee (ACIP) prevention and control of influenza. *MMWR.* 1984;33(19):253-260, 265–6, 270.
 36. Stewart AM. Using state Laws to vaccinate the health-care workforce. *Public Health Rep.* 2012;127(2):224-227.
 37. Rakita RM, Hagar BA, Crome P, Lammert JK. Mandatory influenza vaccination of healthcare workers: a 5-year study. *Infect Control Hosp Epidemiol.* 2010;31(9):881-888. doi:10.1086/656210
 38. Song Y, Millman AJ. Overview and lessons learned for increasing influenza vaccination coverage among healthcare Workers in the United States. *China CDC Wkly.* 2020;2(44):862. doi:10.46234/ccdcw2020.229
 39. Greene MT, Fowler KE, Ratz D, Krein SL, Bradley SF, Saint S. Changes in influenza vaccination requirements for health care personnel in US hospitals. *JAMA Netw Open.* 2018;1(2):e180143. doi:10.1001/jamanetworkopen.2018.0143
 40. Bryce E, Embree J, Evans G, et al. AMMI Canada position paper: 2012 mandatory influenza immunization of health care workers. *Can J Infect Dis Med Microbiol.* 2012;23(4):e93-e95.
 41. Maltezou HC, Botelho-Nevers E, Brantsæter AB, et al. Vaccination of healthcare personnel in Europe: update to current policies. *Vaccine.* 2019;37(52):7576-7584. doi:10.1016/j.vaccine.2019.09.061
 42. Bianchi FP, Cuscianna E, Rizzi D, et al. Impact of COVID-19 pandemic on flu vaccine uptake in healthcare workers in Europe: a systematic review and meta-analysis. *Expert Rev Vaccines.* 2023;22(1):777-784. doi:10.1080/14760584.2023.2250437
 43. Gardam M, Lemieux C. Mandatory influenza vaccination? First we need a better vaccine. *Can Med Assoc J.* 2013;185(8):639-640. doi:10.1503/cmaj.122074
 44. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev.* 2018;(2):CD001269. doi:10.1002/14651858.CD001269.pub6
 45. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane acute respiratory infections group, ed. *Cochrane Database Syst Rev.* 2018;(2). Article number CD004879. doi:10.1002/14651858.CD004879.pub5
 46. Demicheli V, Jefferson T, Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. Cochrane acute respiratory infections group, ed. *Cochrane Database Syst Rev.* 2018;(2). Article number CD004876. doi:10.1002/14651858.CD004876.pub4
 47. Allsup S, Haycox A, Regan M, Gosney M. Is influenza vaccination cost effective for healthy people between ages 65 and 74 years?: a randomised controlled trial. *Vaccine.* 2004;23(5):639-645. doi:10.1016/j.vaccine.2004.07.008

48. Jefferson T, Rivetti A, Demicheli V. Why have three long-running Cochrane Reviews on influenza vaccines been stabilised? Cochrane Community. Published January 29, 2018. Accessed December 20, 2023. <https://community.cochrane.org/news/why-have-three-long-running-cochrane-reviews-influenza-vaccines-been-stabilised>
49. Centers for Disease Control and Prevention. How Flu vaccine effectiveness and efficacy are measured. Published January 6, 2023. Accessed January 12, 2024. <https://t.cdc.gov/55HTJ>
50. Valenciano M, Ciancio B, I-MOVE study team. I-MOVE: a European network to measure the effectiveness of influenza vaccines. *Euro Surveill*. 2012;17(39):20281. doi:10.2807/ese.17.39.20281-en
51. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. *Vaccine*. 2013;31(30):3104-3109. doi:10.1016/j.vaccine.2013.04.026
52. Centers for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness studies. Published February 29, 2024. Accessed March 27, 2024. <https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm>
53. Centers for Disease Control and Prevention. Benefits of Flu vaccination during 2022-2023 Flu season. Published December 13, 2023. Accessed January 13, 2024. <https://www.cdc.gov/flu/about/burden-prevented/2022-2023.htm>
54. Tenforde MW, Weber ZA, Yang DH, et al. Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022–2023. *J Infect Dis*. 2023;jiad542. doi:10.1093/infdis/jiad542
55. Centers for Disease Control and Prevention. Seasonal Flu vaccines. Published August 25, 2023. Accessed January 13, 2024. <https://www.cdc.gov/flu/prevent/flushot.htm>
56. European Centre for Disease Prevention and Control. Seasonal influenza vaccination strategies. Published March 8, 2023. Accessed January 13, 2024. <https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/vaccination-strategies>
57. Wiemken TL, Khan F, Puzniak L, et al. Seasonal trends in COVID-19 cases, hospitalizations, and mortality in the United States and Europe. *Sci Rep*. 2023;13:3886. doi:10.1038/s41598-023-31057-1
58. NHS England. Last chance for people in the Midlands to benefit from COVID booster as vaccinations cease on 12 February. Accessed January 14, 2024. <https://www.england.nhs.uk/midlands/2023/01/26/last-chance-for-people-in-the-midlands-to-benefit-from-covid-booster-as-vaccinations-cease-on-12-february/>
59. Centers for Disease Control and Prevention. CDC recommends updated COVID-19 vaccine for fall/winter virus season. Published September 12, 2023. Accessed January 14, 2024. <https://www.cdc.gov/media/releases/2023/p0912-COVID-19-Vaccine.html>
60. Joint Committee on Vaccination and Immunisation. JCVI Statement on the COVID-19 Vaccination Programme for Autumn 2023, 26 May 2023. Department of Health & Social Care Accessed January 14, 2024. <https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccination-programme-jcvi-advice-26-may-2023/jcvi-statement-on-the-covid-19-vaccination-programme-for-autumn-2023-26-may-2023>
61. Australian Technical Advisory Group on Immunisation. ATAGI recommendations on use of the Moderna and Pfizer monovalent Omicron XBB.1.5 COVID-19 vaccines. Australian Government Department of Health and Aged Care. Published November 20, 2023. Accessed January 14, 2024. <https://www.health.gov.au/news/atagi-recommendations-on-use-of-the-moderna-and-pfizer-monovalent-omicron-xbb15-covid-19-vaccines>
62. The Public Health Agency of Sweden. Vaccination against flu and COVID-19. Published November 7, 2023. Accessed January 14, 2024. <https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/vaccinations/vaccination-against-flu-and-covid-19/>
63. Federal Ministry of Health. Information on coronavirus vaccination. Published September 18, 2023. Accessed January 14, 2024. <https://www.bundesgesundheitsministerium.de/en/coronavirus/faq-covid-19-vaccination>
64. Ministère du travail, de la santé et des solidarités. La vaccination contre le Covid-19. Published October 4, 2023. Accessed January 14, 2024. <https://sante.gouv.fr/soins-et-maladies/maladies/maladies-infectieuses/coronavirus/vaccin-covid-19/la-vaccination-contre-le-covid-19-tout-savoir-tout-comprendre/article/la-vaccination-contre-le-covid-19-tout-savoir-tout-comprendre>
65. Comisión de Salud Pública. Recomendaciones de Vacunación Frente a Gripe y COVID-19 En La Temporada 2023–2024 En España. Actualización. 2023. Accessed January 14, 2024. https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/gripe_covid19/docs/RecomendacionesVacunacion_Gripe-Covid19.pdf
66. Ministero della Salute. Campagna di vaccinazione anti Covid-19 2023/2024. Accessed January 14, 2024. <https://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=6110&area=nuovoCoronavirus&menu=vuoto%20%20https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2023&codLeg=96278&parte=1%20&serie=null>
67. Sistema Nacional Saúde. Vacinação Gripe e COVID-19 | Outono - Inverno 2023–24. Accessed January 14, 2024. <https://www.sns.gov.pt/vacinacao-gripe-e-covid-19-outono-inverno-2023/>
68. Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. *Int J Infect Dis*. 2022;114:252-260. doi:10.1016/j.ijid.2021.11.009
69. Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. *JAMA*. 2021;326(20):2043-2054. doi:10.1001/jama.2021.19499
70. Guetzkow J, Retsef L. Effect of mRNA vaccine manufacturing processes on efficacy and safety still an open question. *BMJ*. 2024;378:o1731.
71. Polack FP, Thomas SJ, Nicholas K, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med*. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577
72. Centers for Disease Control and Prevention. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Updated COVID-19 vaccine (2023-2024 Formulation). Published September 27, 2023. Accessed January 14, 2024. <https://www.cdc.gov/vaccines/acip/recs/grade/covid-19-2023-2024-Monovalent.html>

73. Moreira ED, Kitchin N, Xu X, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. *N Engl J Med*. 2022;386(20):1910-1921. doi:10.1056/NEJMoa2200674
74. Meah S, Shi X, Fritsche LG, et al. Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: a review and case study. *Sci Adv*. 2023;9(51):eadj3747. doi:10.1126/sciadv.adj3747
75. Antunes L, Mazagatos C, Martínez-Baz I, et al. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to august, 2023. *Euro Surveill*. 2024;29(3):2300708. doi:10.2807/1560-7917.ES.2024.29.3.2300708
76. Kirsebom FCM, Harman K, Lunt RJ, et al. Vaccine effectiveness against hospitalisation estimated using a test-negative case-control study design, and comparative odds of hospital admission and severe outcomes with COVID-19 sub-lineages BQ.1, CH.1.1. And XBB.1.5 in England. *Lancet Reg Health - Eur*. 2023;35:100755. doi:10.1016/j.lanepe.2023.100755
77. Chalupka A, Richter L, Chakeri A, et al. Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria. *Eur J Clin Investig*. 2024;54(3):e14136. doi:10.1111/eci.14136
78. Ioannidis JPA. Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies. *BMJ Evid-Based Med*. 2022;27(6):324-329. doi:10.1136/bmjebm-2021-111901
79. Arbel R, Hammerman A, Sergienko R, et al. BNT162b2 vaccine booster and mortality due to Covid-19. *N Engl J Med*. 2021;385(26):2413-2420. doi:10.1056/NEJMoa2115624
80. Høeg TB, Duriseti R, Prasad V. Potential "healthy Vaccinee bias" in a study of BNT162b2 vaccine against Covid-19. *N Engl J Med*. 2023;389(3):284-286. doi:10.1056/NEJMc2306683
81. Sullivan SG, Tchetgen Tchetgen EJ, Cowling BJ. Theoretical basis of the test-negative study Design for Assessment of influenza vaccine effectiveness. *Am J Epidemiol*. 2016;184(5):345-353. doi:10.1093/aje/kww064
82. Ainslie KEC, Shi M, Haber M, Orenstein WA. On the bias of estimates of influenza vaccine effectiveness from test-negative studies. *Vaccine*. 2017;35(52):7297-7301. doi:10.1016/j.vaccine.2017.10.107
83. Sullivan SG, Khvorov A, Huang X, et al. The need for a clinical case definition in test-negative design studies estimating vaccine effectiveness. *Npj Vaccines*. 2023;8(1):1-5. doi:10.1038/s41541-023-00716-9
84. Meester R, Bonte J. The test-negative design: opportunities, limitations and biases. *J Eval Clin Pract*. 2023;30:jep.13888. doi:10.1111/jep.13888
85. Lewnard JA, Patel MM, Jewell NP, et al. Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines. *Epidemiology*. 2021;32(4):508-517. doi:10.1097/EDE.0000000000001366
86. Westreich D, Hudgens MG. Invited commentary: beware the test-negative design. *Am J Epidemiol*. 2016;184(5):354-356. doi:10.1093/aje/kww063
87. National Advisory Committee on Immunization. COVID-19 vaccines: Canadian Immunization Guide. Published December 23, 2021. Accessed January 22, 2024. <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html>
88. Statens Serum Institut. No 39 - This autumn's influenza and COVID-19 vaccination programme. 2023/2024. Published October 25, 2023. Accessed January 20, 2024. <https://en.ssi.dk/news/epi-news/2023/no-39---2023>
89. Pezzullo AM, Axfors C, Contopoulos-Ioannidis DG, Apostolatos A, Ioannidis JPA. Age-stratified infection fatality rate of COVID-19 in the non-elderly population. *Environ Res*. 2023;216:114655. doi:10.1016/j.envres.2022.114655
90. Axfors C, Ioannidis JPA. Infection fatality rate of COVID-19 in community-dwelling elderly populations. *Eur J Epidemiol*. 2022;37(3):235-249. doi:10.1007/s10654-022-00853-w
91. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. *Lancet*. 2011;378(9807):1917-1930. doi:10.1016/S0140-6736(11)61051-9
92. Ghazy RM, Ashmawy R, Hamdy NA, et al. Efficacy and effectiveness of SARS-CoV-2 vaccines: a systematic review and meta-analysis. *Vaccine*. 2022;10(3):350. doi:10.3390/vaccines10030350
93. Wallace M. Evidence to Recommendations Framework: 2023–2024 (Monovalent, XBB Containing) COVID-19 Vaccine. Presented at: ACIP Meeting; Centers for Disease Control and Prevention; September 12, 2023. Accessed January 18, 2024. <https://www.cdc.gov/vaccines/acip/meetings/downloads/slide-s-2023-09-12/11-COVID-Wallace-508.pdf>
94. Kanokudom S, Assawakosri S, Suntronwong N, et al. Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine. *Vaccine*. 2022;10(1):86. doi:10.3390/vaccines10010086
95. Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. *Lancet Infect Dis*. 2022;22(8):1131-1141. doi:10.1016/S1473-3099(22)00271-7
96. Parés-Badell O, Zules-Oña R, Armadans L, et al. Reactogenicity to the mRNA-1273 booster according to previous mRNA COVID-19 vaccination. *Vaccine*. 2022;10(8):1217. doi:10.3390/vaccines10081217
97. Cowling BJ, Thompson MG, Ng TWY, et al. Comparative reactogenicity of enhanced influenza vaccines in older adults. *J Infect Dis*. 2020;222(8):1383-1391. doi:10.1093/infdis/jiaa255
98. Schmader KE, Liu CK, Harrington T, et al. Safety, reactogenicity, and health-related quality of life after trivalent adjuvanted vs trivalent high-dose inactivated influenza vaccines in older adults: a randomized clinical trial. *JAMA Netw Open*. 2021;4(1):e2031266. doi:10.1001/jamanetworkopen.2020.31266
99. Knudsen B, Prasad V. COVID-19 vaccine induced myocarditis in young males: a systematic review. *Eur J Clin Investig*. 2023;53(4):e13947. doi:10.1111/eci.13947
100. Smaardijk VR, Jajou R, Kant A, van Hunsel FPAM. Menstrual disorders following COVID-19 vaccination: a review using a

- systematic search. *Front Drug Saf Regul.* 2024;4. doi:10.3389/fdsfr.2024.1338466
101. Weiland N, LaFraniere S. Two top F.D.A. vaccine regulators are set to depart during a crucial period. *The New York Times*. Published August 31, 2021. Accessed February 8, 2024. <https://www.nytimes.com/2021/08/31/us/politics/fda-vaccine-regulators-booster-shots.html>
 102. Offit PA. Bivalent Covid-19 vaccines — a cautionary tale. *N Engl J Med.* 2023;388(6):481-483. doi:10.1056/NEJMp2215780
 103. Hutto E. Who really needs a yearly COVID booster? MedPage Today Published September 27, 2023. Accessed January 20, 2024. <https://www.medpagetoday.com/infectiousdisease/covid19vaccine/106511>
 104. Marks P, Califf R. Is vaccination approaching a dangerous tipping point? *JAMA.* 2024;331(4):283-284. doi:10.1001/jama.2023.27685
 105. Bird A. The epistemological function of Hill's criteria. *Prev Med.* 2011;53(4-5):242-245. doi:10.1016/j.ypmed.2011.07.009
 106. Backmann M. What's in a gold standard? In defence of randomised controlled trials. *Med Health Care Philos.* 2017;20(4):513-523. doi:10.1007/s11019-017-9773-2
 107. London AJ. Equipose: integrating social value and equal respect in research with humans. In: Iltis AS, MacKay D, eds. *The Oxford Handbook of Research Ethics*. Oxford University Press; 2020. doi:10.1093/oxfordhb/9780190947750.013.13
 108. Barosa M, Jamrozik E, Prasad V. The ethical obligation for research during public health emergencies: insights from the COVID-19 pandemic. *Med Health Care Philos Published Online December.* 2024;27:49-70. doi:10.1007/s11019-023-10184-6
 109. London AJ, Kimmelman J. Against pandemic research exceptionalism. *Science.* 2020;368(6490):476-477. doi:10.1126/science.abc1731
 110. Centers for Disease Control and Prevention. Licensure of a high-dose inactivated influenza vaccine for persons aged ≥65 years (Fluzone high-dose) and guidance for use — United States, 2010. *MMWR Morb Mortal Wkly Rep.* 2010;59(16):485-486.
 111. Food and Drug Administration. Clinical review Memorandum - fluzone high-dose quadrivalent. Published 2019. Accessed 2 May, 2024. <https://www.fda.gov/media/138142/download?attachment>
 112. Yang LPH. Recombinant trivalent influenza vaccine (Flublok®): a review of its use in the prevention of seasonal influenza in adults. *Drugs.* 2013;73(12):1357-1366. doi:10.1007/s40265-013-0103-6
 113. Food and Drug Administration. Center for Biologics Evaluation and Research. June 27, 2014 Approval Letter - Flublok. Published 2014. Accessed May 2, 2024. <http://wayback.archive-it.org/7993/20170723030116/https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm403352.htm>
 114. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA.* 2010;303(12):1180-1187. doi:10.1001/jama.2010.310
 115. Witt CM. Efficacy, effectiveness, pragmatic trials – guidance on terminology and the advantages of pragmatic trials. *Forsch Komplementmed.* 2009;16(5):292-294. doi:10.1159/000234904
 116. Ajmera Y, Singhal S, Dwivedi SN, Dey AB. The changing perspective of clinical trial designs. *Perspect Clin Res.* 2021;12(2):66-71. doi:10.4103/picr.PICR_138_20
 117. Johansen ND, Modin D, Nealon J, et al. A pragmatic randomized feasibility trial of influenza vaccines. *NEJM Evid.* 2023;2(2):EVIDo2200206. doi:10.1056/EVIDo2200206
 118. Johansen ND, Modin D, Skaarup KG, et al. Effectiveness of high-dose versus standard-dose quadrivalent influenza vaccine against recurrent hospitalizations and mortality in relation to influenza circulation: a post-hoc analysis of the DANFLU-1 randomized clinical trial. *Clin Microbiol Infect.* 2024. doi:10.1016/j.cmi.2024.01.017
 119. Johansen ND. DANFLU-1: Feasibility of a pragmatic randomized trial to assess the relative effectiveness of high-dose vs. standard-dose quadrivalent influenza vaccine on severe cardio-respiratory outcomes in elderly adults. Presented at: ESC Congress 2022. Accessed January 6, 2024. https://clinicaltrialsreults.org/wp-content/uploads/2022/08/Johansen_DANFLU-1.pdf
 120. A pragmatic randomized trial to evaluate the effectiveness of high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in older adults (DANFLU-2). Identifier NCT05517174. Accessed January 10, 2024. <https://classic.clinicaltrials.gov/ct2/show/NCT05517174>
 121. Hsing AW, Ioannidis JPA. Nationwide population science: lessons from the Taiwan National Health Insurance Research Database. *JAMA Intern Med.* 2015;175(9):1527-1529. doi:10.1001/jamainternmed.2015.3540
 122. Burgess T, Richard SA, Collins L, et al. 2206. Pragmatic assessment of influenza vaccine effectiveness in the Department of Defense (PAIVED): updates from year 4 of a multi-site trial. *Open Forum Infect Dis.* 2022;9(Supplement_2):ofac492.1825. doi:10.1093/ofid/ofac492.1825
 123. Hayward AC, Harling R, Wetten S, et al. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. *BMJ.* 2006;333(7581):1241. doi:10.1136/bmj.39010.581354.55
 124. Gravenstein S, Davidson HE, Taljaard M, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial. *Lancet Respir Med.* 2017;5(9):738-746. doi:10.1016/S2213-2600(17)30235-7
 125. Hsiao A, Yee A, Fireman B, Hansen J, Lewis N, Klein NP. Recombinant or standard-dose influenza vaccine in adults under 65 years of age. *N Engl J Med.* 2023;389(24):2245-2255. doi:10.1056/NEJMoa2302099
 126. Vardeny O, Kim K, Udell JA, et al. Effect of high-dose trivalent vs standard-dose Quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. *JAMA.* 2021;325(1):39-49. doi:10.1001/jama.2020.23649
 127. Janiaud P, Dal-Ré R, Ioannidis JPA. Assessment of pragmatism in recently published randomized clinical trials. *JAMA Intern Med.* 2018;178(9):1278-1280. doi:10.1001/jamainternmed.2018.3321
 128. Mc Cord KA, Al-Shahi Salman R, Treweek S, et al. Routinely collected data for randomized trials: promises, barriers, and implications. *Trials.* 2018;19(1):29. doi:10.1186/s13063-017-2394-5
 129. Mc Cord KA, Ewald H, Agarwal A, et al. Treatment effects in randomised trials using routinely collected data for outcome

- assessment versus traditional trials: meta-research study. *BMJ*. 2021;372:n450. doi:[10.1136/bmj.n450](https://doi.org/10.1136/bmj.n450)
130. Koenig F, Spiertz C, Millar D, et al. Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL. *eClinicalMedicine*. 2024;67:102384. doi:[10.1016/j.eclinm.2023.102384](https://doi.org/10.1016/j.eclinm.2023.102384)
131. Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus Prefusion F protein vaccine in older adults. *N Engl J Med*. 2023;388(7):595-608. doi:[10.1056/NEJMoa2209604](https://doi.org/10.1056/NEJMoa2209604)

How to cite this article: Barosa M, Ioannidis JPA, Prasad V. Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies. *Eur J Clin Invest*. 2024;54:e14286. doi:[10.1111/eci.14286](https://doi.org/10.1111/eci.14286)